Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2007-002548-12Phase 2Completed
Phase 2, randomised, open-label trial in hematopoietic malignancies comparing 2 Gy TBI + fludarabine conditioning with 8 Gy TLI + ATG conditioning (2 arms). Primary endpoint: Grade II-IV acute graft-versus-host disease incidence. Started Dec 2007; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2007-002548-12.